Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.
Corrie P. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
A GENOMEWIDE ASSOCIATION STUDY IDENTIFIES NOVEL LOCI THAT PREDISPOSE TO MYELOPROLIFERATIVE NEOPLASMS
Jones A. et al, (2013), HAEMATOLOGICA, 98, 221 - 222
Tumour lysis syndrome in a patient with intravascular spread from a recurrent epithelial ovarian cancer
Camarata M. et al, (2013), BMJ Case Reports
Germline counterparts of oncogenic mutations: who gives a JAK?.
Mead AJ. et al, (2013), Oncotarget, 4, 814 - 815
A phase I study of oral rucaparib in combination with carboplatin.
Molife LR. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence.
Corrw P. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
Gupta A. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
Ipilimumab in the real world: The UK expanded access programme (EAP) experience in advanced melanoma.
Ahmad S. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
Phase II double-blind, randomized study of selumetinib (SEL) plus dacarbazine (DTIC) versus placebo (PBO) plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma
Middleton MR. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
Phase II trial of nemorubicin hydrochloride (N) in combination with cisplatin (cDDP) administered by intra-hepatic artery (IHA) in patients (pts) with hepatocellular carcinoma (HCC): Final results.
Izzo F. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
Safety, pharmacokinetics, and preliminary activity of the alpha-specific PI3K inhibitor BYL719: Results from the first-in-human study.
Gonzalez-Angulo AM. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
Impact of isolated germline JAK2V617I mutation on human hematopoiesis.
Mead AJ. et al, (2013), Blood, 121, 4156 - 4165
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP.
Lu M. et al, (2013), Cancer Cell, 23, 618 - 633
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Plummer R. et al, (2013), Cancer Chemother Pharmacol, 71, 1191 - 1199
Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia: a reply to a rebuttal.
Psaila B. et al, (2013), J Thromb Haemost, 11, 1002 - 1003
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.
Ong CC. et al, (2013), J Natl Cancer Inst, 105, 606 - 607
Tumour lysis syndrome in a patient with intravascular spread from a recurrent epithelial ovarian cancer.
Camarata M. et al, (2013), BMJ Case Rep, 2013
IMCgp100: a novel bispecific biologic for the treatment of malignant melanoma.
Middleton M. et al, (2013), CANCER RESEARCH, 73
Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.
Shaboodien R. et al, (2013), Int J Gynecol Cancer, 23, 481 - 487